Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Feb 27;16(5):671.
doi: 10.3390/nu16050671.

The Role of Probiotics in the Prevention of Clostridioides difficile Infection in Patients with Chronic Kidney Disease

Sylwia Dudzicz-Gojowy  1 , Andrzej Więcek  1 , Marcin Adamczak  1
Affiliations
Review

The Role of Probiotics in the Prevention of Clostridioides difficile Infection in Patients with Chronic Kidney Disease

Sylwia Dudzicz-Gojowy et al. Nutrients. .

Abstract

In patients suffering from chronic kidney disease (CKD), substantial unfavourable alterations in the intestinal microbiota composition, i.e., dysbiosis, have been noted. The main causes of such dysbiosis among others are insufficient dietary fibre content in the diet, fluid restrictions, medications used, and physical activity limitation. One clinically important consequence of dysbiosis in CKD patients is high risk of Clostridioides difficile infection (CDI). In observational studies, it was found that CDI is more frequent in CKD patients than in the general population. This appears to be related to high hospitalization rate and more often antibiotic therapy use, leading up to the occurrence of dysbiosis. Therefore, the use of probiotics in CKD patients may avert changes in the intestinal microbiota, which is the major risk factor of CDI. The aim of this review paper is to summarize the actual knowledge concerning the use of probiotics in CDI prevention in CKD patients in the context of CDI prevention in the general population.

Keywords: Clostridioides difficile infection; chronic kidney disease; probiotics.

PubMed Disclaimer

Conflict of interest statement

Marcin Adamczak received a lecturer fee from Sanprobi. The other authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Flow chart of identification of eligible articles.
Figure 2
Figure 2
Flow chart of identification of eligible articles.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Czepiel J., Dróżdż M., Pituch H., Kuijper E.J., Perucki W., Mielimonka A., Goldman S., Wultańska D., Garlicki A., Biesiada G. Clostridium difficile infection: Review. Eur. J. Clin. Microbiol. Infect. Dis. 2019;38:1211–1221. doi: 10.1007/s10096-019-03539-6. - DOI - PMC - PubMed
    1. Sundström J., Bodegard J., Bollmann A., Vervloet M.G., Mark P.B., Karasik A., Taveira-Gomes T., Botana M., Birkeland K.I., Thuresson M., et al. Prevalence, outcomes, and cost of chronic kidney disease in a contemporary population of 2·4 million patients from 11 countries: The CaReMe CKD study. Lancet Reg. Health Eur. 2022;20:100438. doi: 10.1016/j.lanepe.2022.100438. - DOI - PMC - PubMed
    1. Keddis M.T., Khanna S., Noheria A., Baddour L.M., Pardi D.S., Qian Q. Clostridium difficile infection in patients with chronic kidney disease. Mayo Clin. Proc. 2012;87:1046–1053. doi: 10.1016/j.mayocp.2012.05.025. - DOI - PMC - PubMed
    1. Cooper C.C., Jump R.L., Chopra T. Prevention of infection due to Clostridium difficile. Infect. Dis. Clin. N. Am. 2016;30:999–1012. doi: 10.1016/j.idc.2016.07.005. - DOI - PubMed
    1. Plata C., Cruz C., Cervantes L.G., Ramírez V. The gut microbiota and its relationship with chronic kidney disease. Int. Urol. Nephrol. 2019;51:2209–2226. doi: 10.1007/s11255-019-02291-2. - DOI - PubMed

MeSH terms

Substances